Aytu Biopharma (AYTU) Current Deferred Revenue (2014 - 2020)

Aytu Biopharma (AYTU) posted quarterly Current Deferred Revenue of $475680.0 for Q4 2020, up 104.53% quarter-over-quarter from $232576.0 in Q3 2020.

Aytu Biopharma (AYTU) Current Deferred Revenue (2014 - 2020) Analysis & Trends

Aytu Biopharma (AYTU) has reported Current Deferred Revenue for 6 consecutive years, with $475680.0 the latest figure, recorded in Q4 2020.

In Q4 2020, Current Deferred Revenue changed N/A year-over-year to $475680.0; the TTM figure through Dec 2020 stood at $475680.0 (changed N/A YoY), while the FY2020 annual figure was $339336.0, changed N/A from the prior year.
Current Deferred Revenue climbed to $475680.0 in Q4 2020 per AYTU's latest filing, from $232576.0 in the prior quarter.
Across five years, Current Deferred Revenue topped out at $475680.0 in Q4 2020 and bottomed at $1450.0 in Q2 2018.
Historically, Current Deferred Revenue has averaged $128421.1 across 4 years, with a median of $6673.0 in 2017.
On a YoY basis, Current Deferred Revenue climbed as much as 78.27% in 2018 and fell as far as 78.27% in 2018.
Aytu Biopharma's Current Deferred Revenue stood at $85714.0 in 2016, then tumbled by 94.42% to $4787.0 in 2017, then plunged by 69.71% to $1450.0 in 2018, then jumped by 32705.52% to $475680.0 in 2020.
Business Quant data shows AYTU's Current Deferred Revenue at $475680.0 in Q4 2020, $232576.0 in Q3 2020, and $339336.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-
10	Aytu Biopharma	24.70 Mn	-2.01 Mn	7.60 Mn

Download Data